Cesca Therapeutics Inc., the Rancho Cordova-based medical equipment firm, reported a loss of $4.4 million, or 11 cents per share, for its fiscal second quarter ended Dec. 31.
That compares with a loss of $1.6 million, or 10 cents a share, in the same period of 2013.
In its quarterly earnings report, Cesca said the increased year-over-year loss was related to “investments in the development and advancement of the company’s clinical programs and legal costs associated with patent litigation.”
Revenue in the most recent quarter was $4.6 million, compared with $4.5 million for the same period in the prior year.
Sign Up and Save
Get six months of free digital access to The Sacramento Bee
Cesca does research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The firm has developed automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
Also this week, Cesca announced that the India Drug Controller General has approved import and commercialization of Cesca’s MarrowXpress system in India. The MXP isolates and concentrates stem cells from bone marrow.
Call The Bee’s Mark Glover, (916) 321-1184.